enVVeno Medical Corporation NVNO

NVNO Company Overview

enVVeno Medical Corporation (NASDAQ: NVNO) is a U.S.-based medical technology company focused on developing implantable devices for the treatment of chronic deep venous disease (CVD), particularly deep venous reflux and venous obstruction. The company operates within the vascular medical device and minimally invasive therapeutics industries, targeting conditions associated with chronic venous insufficiency that can lead to pain, swelling, venous ulcers, and reduced mobility. Its primary products under development are the VenoValve and enVVe systems, both designed to address venous valve failure in the deep venous system, an area with limited approved treatment options in the United States.

The company’s core revenue strategy is tied to the clinical development, regulatory approval, and future commercialization of its venous implant technologies. enVVeno Medical has positioned itself as a specialized innovator focused on unmet needs in venous disease treatment, particularly for patients who are not adequately treated with compression therapy or existing endovascular procedures. The company evolved from technologies initially developed under Hancock Jaffe Laboratories before rebranding and focusing exclusively on venous disease therapeutics. Public filings and investor materials indicate that its strategic differentiation is based on proprietary bioprosthetic valve technology designed for long-term implantation in the deep venous system.